TheraSphere (yttrium 90 microspheres)

P1, N=65, Recruiting, University of Michigan Rogel Cancer Center | N=45 --> 65

P2, N=30, Not yet recruiting, University of Miami

P=N/A, N=7, Terminated, Northwestern University | N=20 --> 7 | Trial completion date: Apr 2025 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2025 --> Apr 2024; Low enrollment

P2, N=100, Recruiting, AstraZeneca | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jul 2026 --> Oct 2026

P3, N=92, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Dec 2025

Careful patient selection, including consideration of the prognostic factors ECOG, baseline CEA, and KRAS status, sets outcome expectations in patients with colorectal liver metastases suitable for TARE/Chemo as second-line treatment (Trial Registry Number: NCT01483027).

P1/2, N=25, Not yet recruiting, Jonsson Comprehensive Cancer Center

P2, N=100, Recruiting, Boston Scientific Corporation | Trial primary completion date: Dec 2026 --> Jun 2027

P=N/A, N=20, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting

P=N/A, N=36, Suspended, Boston Scientific Corporation | Recruiting --> Suspended

P=N/A, N=202, Completed, Ankara University | Not yet recruiting --> Completed | N=350 --> 202 | Initiation date: Sep 2023 --> Jan 2024

P1, N=12, Recruiting, Boston Scientific Corporation | Trial primary completion date: Jun 2024 --> Dec 2024

P2, N=100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P1, N=2, Terminated, Northwestern University | Trial completion date: Dec 2022 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Oct 2023; Lack of funding

P=N/A, N=36, Recruiting, Boston Scientific Corporation | Not yet recruiting --> Recruiting

P=N/A, N=500, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting

P2, N=100, Not yet recruiting, AstraZeneca | Initiation date: Sep 2023 --> Jan 2024

P=N/A, N=0, Approved for marketing, University of California, Irvine | N=186 --> 0

P=N/A, N=36, Not yet recruiting, Boston Scientific Corporation

P=N/A, N=50, Recruiting, Ochsner Health System

P1, N=12, Recruiting, Boston Scientific Corporation | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Jun 2024

P2, N=30, Recruiting, Seoul National University Hospital

P=N/A, N=50, Recruiting, Ochsner Health System | Not yet recruiting --> Recruiting

P3, N=90, Recruiting, Boston Scientific Corporation | Trial completion date: Apr 2026 --> Oct 2026 | Trial primary completion date: Dec 2024 --> Jun 2025

P=N/A, N=5, Completed, Boston Scientific Corporation | Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Jun 2023

A panel of Human HCC cell lines (HepG2 and PLC/PRF/5 characterized by high expression of hepatocyte and liver progenitor genes, and SNU-449 and SNU-423, characterized by high expression of stem cell and epithelial-mesenchymal transition genes) and a selected tumoroid were treated at escalating activities (0-20 MBq/ml) of glass Y-90 microspheres (Therasphere, Boston Scientific) for 10 days in vitro... HCC cell lines and tumoroids demonstrate heterogenous sensitivity to Y-90 microsphere treatment in vitro, potentially reflected by underlying transcriptomic profiles. Establishing patient derived HCC tumoroids for in vitro Y-90 microsphere treatment screens is feasible and serves as a powerful platform to assess biological underpinnings of Y-90-RE response with the advantage of being linked to clinical metadata.

P2, N=100, Recruiting, Boston Scientific Corporation | Trial completion date: Sep 2027 --> Jun 2027 | Trial primary completion date: Jul 2027 --> Dec 2026

P=N/A, N=50, Not yet recruiting, Ochsner Health System

P2, N=100, Recruiting, Boston Scientific Corporation | Suspended --> Recruiting | N=150 --> 100 | Trial primary completion date: Mar 2027 --> Jul 2027

P=N/A, N=5, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting

P=N/A, N=5, Recruiting, Boston Scientific Corporation | Trial completion date: May 2023 --> Aug 2023 | Trial primary completion date: May 2023 --> Aug 2023

P2, N=150, Suspended, Boston Scientific Corporation | Trial completion date: May 2028 --> Jul 2027

First-line treatment of ICC with radioembolization showed promising OS and minimal toxicity, especially in patients with solitary tumor. Radioembolization may be considered as the first line treatment of unresectable ICC.

P=N/A, N=20, Recruiting, Northwestern University | Trial primary completion date: Apr 2023 --> Apr 2025

P2, N=150, Suspended, Boston Scientific Corporation | Trial completion date: Nov 2026 --> May 2028 | Recruiting --> Suspended | Trial primary completion date: Nov 2026 --> May 2027

P=N/A, N=186, Completed, University of California, Irvine | Recruiting --> Completed | N=130 --> 186 | Trial completion date: Oct 2021 --> Feb 2022 | Trial primary completion date: Oct 2021 --> Feb 2022

P=N/A, N=299, Completed, M.D. Anderson Cancer Center | Unknown status --> Completed

P1, N=290, Completed, Ohio State University Comprehensive Cancer Center | Recruiting --> Completed | Phase classification: PN/A --> P1 | N=800 --> 290

P2, N=150, Recruiting, Boston Scientific Corporation | Not yet recruiting --> Recruiting

Real-world data confirmed a significant association between TAD and OR, TAD and OS, and TAD and AFP response. No association was found between ≥ grade 3 hyperbilirubinemia and NTAD.

P2, N=150, Not yet recruiting, Boston Scientific Corporation | Trial completion date: Jun 2025 --> Mar 2026 | Trial primary completion date: Jun 2025 --> Mar 2026

At the 3-month follow-up the radiographic objective response rate was 46.6% and disease control rate was 70%. The treatment of patients with liver-dominant chemotherapy-refractory breast cancer metastases with TARE using yttrium-90 labeled glass microspheres is safe and led to promising hepatic disease control and OS especially in patients with ER+ tumors and in patients without extrahepatic extraosseous metastases.